{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:10Z","timestamp":1792782670195,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Swedish governmental funding of clinical research"},{"DOI":"10.13039\/501100009751","name":"Franke och Margareta Bergqvists Stiftelse f\u00f6r Fr\u00e4mjande av Cancerforskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009751","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Histopathological diagnosis of pulmonary tumors is essential for treatment decisions. The distinction between primary lung adenocarcinoma and pulmonary metastasis from the gastrointestinal (GI) tract may be difficult. Therefore, we compared the diagnostic value of several immunohistochemical markers in pulmonary tumors. Tissue microarrays from 629 resected primary lung cancers and 422 resected pulmonary epithelial metastases from various sites (whereof 275 colorectal cancer) were investigated for the immunohistochemical expression of CDH17, GPA33, MUC2, MUC6, SATB2, and SMAD4, for comparison with CDX2, CK20, CK7, and TTF-1. The most sensitive markers for GI origin were GPA33 (positive in 98%, 60%, and 100% of pulmonary metastases from colorectal cancer, pancreatic cancer, and other GI adenocarcinomas, respectively), CDX2 (99\/40\/100%), and CDH17 (99\/0\/100%). In comparison, SATB2 and CK20 showed higher specificity, with expression in 5% and 10% of mucinous primary lung adenocarcinomas and both in 0% of TTF-1-negative non-mucinous primary lung adenocarcinomas (25\u201350% and 5\u201316%, respectively, for GPA33\/CDX2\/CDH17). MUC2 was negative in all primary lung cancers, but positive only in less than half of pulmonary metastases from mucinous adenocarcinomas from other organs. Combining six GI markers did not perfectly separate primary lung cancers from pulmonary metastases including subgroups such as mucinous adenocarcinomas or CK7-positive GI tract metastases. This comprehensive comparison suggests that CDH17, GPA33, and SATB2 may be used as equivalent alternatives to CDX2 and CK20. However, no single or combination of markers can categorically distinguish primary lung cancers from metastatic GI tract cancer.<\/jats:p>","DOI":"10.1007\/s00428-023-03583-w","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T07:20:21Z","timestamp":1687504821000},"page":"347-357","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Diagnostic gastrointestinal markers in primary lung cancer and pulmonary metastases"],"prefix":"10.1007","volume":"485","author":[{"given":"Karina","family":"Malmros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halla","family":"Vidarsdottir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jirstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Nodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Botling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna S. M.","family":"Mattsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Micke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Planck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Staaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7402-138X","authenticated-orcid":false,"given":"Hans","family":"Brunnstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"3583_CR1","volume-title":"Thoracic tumours","author":"The WHO Classification of Tumours Editorial Board","year":"2021","unstructured":"The WHO Classification of Tumours Editorial Board (2021) Thoracic tumours. IARC Press, Lyon (France)"},{"key":"3583_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","volume":"14","author":"Y Yatabe","year":"2019","unstructured":"Yatabe Y, Dacic S, Borczuk AC et al (2019) Best practices recommendations for diagnostic immunohistochemistry in lung cancer. J Thorac Oncol 14:377\u2013407. https:\/\/doi.org\/10.1016\/j.jtho.2018.12.005","journal-title":"J Thorac Oncol"},{"key":"3583_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1200\/JCO.2008.17.0043","volume":"27","author":"VK Anagnostou","year":"2009","unstructured":"Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL (2009) Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 27:271\u2013278. https:\/\/doi.org\/10.1200\/JCO.2008.17.0043","journal-title":"J Clin Oncol"},{"key":"3583_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/ajcp\/aqy083","volume":"150","author":"H Vidarsdottir","year":"2018","unstructured":"Vidarsdottir H, Tran L, Nodin B et al (2018) Comparison of three different TTF-1 clones in resected primary lung cancer and epithelial pulmonary metastases. Am J Clin Pathol 150:533\u2013544. https:\/\/doi.org\/10.1093\/ajcp\/aqy083","journal-title":"Am J Clin Pathol"},{"key":"3583_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.5606\/tgkdc.dergisi.2020.18196","volume":"28","author":"M Musayeva","year":"2020","unstructured":"Musayeva M, Sak SD, Ozakinci H, Boyacigil S, Coskun O (2020) Evaluation of epidermal growth factor receptor mutations and thyroid transcription factor-1 status in Turkish non-small cell lung carcinoma patients: a study of 600 cases from a single center. Turk Gogus Kalp Damar Cerrahisi Derg 28:143\u2013150. https:\/\/doi.org\/10.5606\/tgkdc.dergisi.2020.18196","journal-title":"Turk Gogus Kalp Damar Cerrahisi Derg"},{"key":"3583_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5146\/tjpath.2020.01503","volume":"37","author":"P Bulutay","year":"2021","unstructured":"Bulutay P, AkyUrek N, Memi SL (2021) Clinicopathological and prognostic significance of the EML4-ALK translocation and IGFR1, TTF1, napsin A expression in patients with lung adenocarcinoma. Turk Patoloji Derg 37:7\u201317. https:\/\/doi.org\/10.5146\/tjpath.2020.01503","journal-title":"Turk Patoloji Derg"},{"key":"3583_CR7","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/1066896914527609","volume":"22","author":"G Rossi","year":"2014","unstructured":"Rossi G, Cavazza A, Righi L et al (2014) Napsin-A, TTF-1, EGFR, and ALK status determination in lung primary and metastatic mucin-producing adenocarcinomas. Int J Surg Pathol 22:401\u2013407. https:\/\/doi.org\/10.1177\/1066896914527609","journal-title":"Int J Surg Pathol"},{"key":"3583_CR8","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41379-020-00690-w","volume":"34","author":"S Kishikawa","year":"2021","unstructured":"Kishikawa S, Hayashi T, Saito T et al (2021) Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma. Mod Pathol 34:786\u2013797. https:\/\/doi.org\/10.1038\/s41379-020-00690-w","journal-title":"Mod Pathol"},{"key":"3583_CR9","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1007\/s00432-021-03609-3","volume":"147","author":"D Ueda","year":"2021","unstructured":"Ueda D, Ito M, Tsutani Y et al (2021) Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung. J Cancer Res Clin Oncol 147:3709\u20133718. https:\/\/doi.org\/10.1007\/s00432-021-03609-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"3583_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1309\/UMF7-15KR-G2V1-98YD","volume":"122","author":"RS Saad","year":"2004","unstructured":"Saad RS, Cho P, Silverman JF, Liu Y (2004) Usefulness of Cdx2 in separating mucinous bronchioloalveolar adenocarcinoma of the lung from metastatic mucinous colorectal adenocarcinoma. Am J Clin Pathol 122:421\u2013427. https:\/\/doi.org\/10.1309\/UMF7-15KR-G2V1-98YD","journal-title":"Am J Clin Pathol"},{"key":"3583_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/00129039-200503000-00009","volume":"13","author":"RM Mazziotta","year":"2005","unstructured":"Mazziotta RM, Borczuk AC, Powell CA, Mansukhani M (2005) CDX2 immunostaining as a gastrointestinal marker: expression in lung carcinomas is a potential pitfall. Appl Immunohistochem Mol Morphol 13:55\u201360. https:\/\/doi.org\/10.1097\/00129039-200503000-00009","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"3583_CR12","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1097\/PAS.0b013e3182299c25","volume":"35","author":"PG Chu","year":"2011","unstructured":"Chu PG, Chung L, Weiss LM, Lau SK (2011) Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol 35:1830\u20131836. https:\/\/doi.org\/10.1097\/PAS.0b013e3182299c25","journal-title":"Am J Surg Pathol"},{"key":"3583_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.humpath.2018.10.009","volume":"84","author":"H Vidarsdottir","year":"2019","unstructured":"Vidarsdottir H, Tran L, Nodin B et al (2019) Immunohistochemical profiles in primary lung cancers and epithelial pulmonary metastases. Hum Pathol 84:221\u2013230. https:\/\/doi.org\/10.1016\/j.humpath.2018.10.009","journal-title":"Hum Pathol"},{"key":"3583_CR14","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13000-021-01184-2","volume":"17","author":"B Alabdullah","year":"2022","unstructured":"Alabdullah B, Hadji-Ashrafy A (2022) Identification of the most specific markers to differentiate primary pulmonary carcinoma from metastatic gastrointestinal carcinoma to the lung. Diagn Pathol 17:7. https:\/\/doi.org\/10.1186\/s13000-021-01184-2","journal-title":"Diagn Pathol"},{"key":"3583_CR15","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/modpathol.2008.107","volume":"21","author":"MC Su","year":"2008","unstructured":"Su MC, Yuan RH, Lin CY, Jeng YM (2008) Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system. Mod Pathol 21:1379\u20131386. https:\/\/doi.org\/10.1038\/modpathol.2008.107","journal-title":"Mod Pathol"},{"key":"3583_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1309\/AJCPKSHXI3XEHW1J","volume":"138","author":"NC Panarelli","year":"2012","unstructured":"Panarelli NC, Yantiss RK, Yeh MM, Liu Y, Chen YT (2012) Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. Am J Clin Pathol 138:211\u2013222. https:\/\/doi.org\/10.1309\/AJCPKSHXI3XEHW1J","journal-title":"Am J Clin Pathol"},{"key":"3583_CR17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.5858\/arpa.2013-0452-OA","volume":"138","author":"F Lin","year":"2014","unstructured":"Lin F, Shi J, Zhu S et al (2014) Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine. Arch Pathol Lab Med 138:1015\u20131026. https:\/\/doi.org\/10.5858\/arpa.2013-0452-OA","journal-title":"Arch Pathol Lab Med"},{"key":"3583_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5858\/arpa.2015-0404-OA","volume":"141","author":"D Altree-Tacha","year":"2017","unstructured":"Altree-Tacha D, Tyrrell J, Haas T (2017) CDH17 is a more sensitive marker for gastric adenocarcinoma than CK20 and CDX2. Arch Pathol Lab Med 141:144\u2013150. https:\/\/doi.org\/10.5858\/arpa.2015-0404-OA","journal-title":"Arch Pathol Lab Med"},{"key":"3583_CR19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3892\/ijo.9.3.465","volume":"9","author":"P Garinchesa","year":"1996","unstructured":"Garinchesa P, Sakamoto J, Welt S, Real F, Rettig W, Old L (1996) Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. Int J Oncol 9:465\u2013471. https:\/\/doi.org\/10.3892\/ijo.9.3.465","journal-title":"Int J Oncol"},{"key":"3583_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/his.13194","volume":"71","author":"N Wong","year":"2017","unstructured":"Wong N, Adamczyk LA, Evans S, Cullen J, Oniscu A, Oien KA (2017) A33 shows similar sensitivity to but is more specific than CDX2 as an immunomarker of colorectal carcinoma. Histopathology 71:34\u201341. https:\/\/doi.org\/10.1111\/his.13194","journal-title":"Histopathology"},{"key":"3583_CR21","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/PAS.0b013e31821c3dae","volume":"35","author":"K Magnusson","year":"2011","unstructured":"Magnusson K, de Wit M, Brennan DJ et al (2011) SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol 35:937\u2013948. https:\/\/doi.org\/10.1097\/PAS.0b013e31821c3dae","journal-title":"Am J Surg Pathol"},{"key":"3583_CR22","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1309\/AJCPWW2URZ9JKQJU","volume":"141","author":"A Dragomir","year":"2014","unstructured":"Dragomir A, de Wit M, Johansson C, Uhlen M, Ponten F (2014) The role of SATB2 as a diagnostic marker for tumors of colorectal origin: results of a pathology-based clinical prospective study. Am J Clin Pathol 141:630\u2013638. https:\/\/doi.org\/10.1309\/AJCPWW2URZ9JKQJU","journal-title":"Am J Clin Pathol"},{"key":"3583_CR23","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/PAS.0000000000001116","volume":"42","author":"C Ma","year":"2018","unstructured":"Ma C, Olevian DC, Lowenthal BM et al (2018) Loss of SATB2 expression in colorectal carcinoma is associated with DNA mismatch repair protein deficiency and BRAF mutation. Am J Surg Pathol 42:1409\u20131417. https:\/\/doi.org\/10.1097\/PAS.0000000000001116","journal-title":"Am J Surg Pathol"},{"key":"3583_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.5858\/arpa.2021-0317-OA","volume":"147","author":"D Dum","year":"2023","unstructured":"Dum D, Kromm D, Lennartz M et al (2023) SATB2 expression in human tumors. Arch Pathol Lab Med 147:451\u2013464. https:\/\/doi.org\/10.5858\/arpa.2021-0317-OA","journal-title":"Arch Pathol Lab Med"},{"key":"3583_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1309\/9R66-73QE-C06D-86Y4","volume":"122","author":"SK Lau","year":"2004","unstructured":"Lau SK, Weiss LM, Chu PG (2004) Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol 122:61\u201369. https:\/\/doi.org\/10.1309\/9R66-73QE-C06D-86Y4","journal-title":"Am J Clin Pathol"},{"key":"3583_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/SLA.0b013e31828cd008","volume":"258","author":"N Ideno","year":"2013","unstructured":"Ideno N, Ohtsuka T, Kono H et al (2013) Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype. Ann Surg 258:141\u2013151. https:\/\/doi.org\/10.1097\/SLA.0b013e31828cd008","journal-title":"Ann Surg"},{"key":"3583_CR27","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/modpathol.2013.101","volume":"26","author":"MD Walsh","year":"2013","unstructured":"Walsh MD, Clendenning M, Williamson E et al (2013) Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol 26:1642\u20131656. https:\/\/doi.org\/10.1038\/modpathol.2013.101","journal-title":"Mod Pathol"},{"key":"3583_CR28","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00534-006-1169-2","volume":"14","author":"K Nagata","year":"2007","unstructured":"Nagata K, Horinouchi M, Saitou M et al (2007) Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg 14:243\u2013254. https:\/\/doi.org\/10.1007\/s00534-006-1169-2","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"3583_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.4132\/jptm.2015.03.27","volume":"49","author":"JS Pyo","year":"2015","unstructured":"Pyo JS, Sohn JH, Kang G et al (2015) MUC2 expression is correlated with tumor differentiation and inhibits tumor invasion in gastric carcinomas: a systematic review and meta-analysis. J Pathol Transl Med 49:249\u2013256. https:\/\/doi.org\/10.4132\/jptm.2015.03.27","journal-title":"J Pathol Transl Med"},{"key":"3583_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00428-016-1970-5","volume":"469","author":"J Betge","year":"2016","unstructured":"Betge J, Schneider NI, Harbaum L et al (2016) MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. Virchows Arch 469:255\u2013265. https:\/\/doi.org\/10.1007\/s00428-016-1970-5","journal-title":"Virchows Arch"},{"key":"3583_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.humpath.2022.05.018","volume":"127","author":"SJ Kim","year":"2022","unstructured":"Kim SJ, Choi SJ, Yang J et al (2022) Pancreatic ductal adenocarcinoma with a predominant large duct pattern has better recurrence-free survival than conventional pancreatic ductal adenocarcinoma: a comprehensive histopathological, immunohistochemical, and mutational study. Hum Pathol 127:39\u201349. https:\/\/doi.org\/10.1016\/j.humpath.2022.05.018","journal-title":"Hum Pathol"},{"key":"3583_CR32","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/his.13894","volume":"75","author":"LL Ritterhouse","year":"2019","unstructured":"Ritterhouse LL, Wu EY, Kim WG et al (2019) Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas. Histopathology 75:546\u2013551. https:\/\/doi.org\/10.1111\/his.13894","journal-title":"Histopathology"},{"key":"3583_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/modpathol.2013.146","volume":"27","author":"AM Krasinskas","year":"2014","unstructured":"Krasinskas AM, Chiosea SI, Pal T, Dacic S (2014) KRAS mutational analysis and immunohistochemical studies can help distinguish pancreatic metastases from primary lung adenocarcinomas. Mod Pathol 27:262\u2013270. https:\/\/doi.org\/10.1038\/modpathol.2013.146","journal-title":"Mod Pathol"},{"key":"3583_CR34","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/dc.20715","volume":"35","author":"S Ali","year":"2007","unstructured":"Ali S, Cohen C, Little JV, Sequeira JH, Mosunjac MB, Siddiqui MT (2007) The utility of SMAD4 as a diagnostic immunohistochemical marker for pancreatic adenocarcinoma, and its expression in other solid tumors. Diagn Cytopathol 35:644\u2013648. https:\/\/doi.org\/10.1002\/dc.20715","journal-title":"Diagn Cytopathol"},{"key":"3583_CR35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1038\/s41598-018-37722-0","volume":"9","author":"P Micke","year":"2019","unstructured":"Micke P, Botling J, Mattsson JSM et al (2019) Mucin staining is of limited value in addition to basic immunohistochemical analyses in the diagnostics of non-small cell lung cancer. Sci Rep 9:1319. https:\/\/doi.org\/10.1038\/s41598-018-37722-0","journal-title":"Sci Rep"},{"key":"3583_CR36","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.5858\/arpa.2019-0250-OA","volume":"144","author":"J Staaf","year":"2020","unstructured":"Staaf J, Tran L, Soderlund L et al (2020) Diagnostic value of insulinoma-associated protein 1 (INSM1) and comparison with established neuroendocrine markers in pulmonary cancers. Arch Pathol Lab Med 144:1075\u20131085. https:\/\/doi.org\/10.5858\/arpa.2019-0250-OA","journal-title":"Arch Pathol Lab Med"},{"key":"3583_CR37","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jtho.2016.01.020","volume":"11","author":"P Micke","year":"2016","unstructured":"Micke P, Mattsson JS, Djureinovic D et al (2016) The impact of the fourth edition of the WHO classification of lung tumours on histological classification of resected pulmonary NSCCs. J Thorac Oncol 11:862\u2013872. https:\/\/doi.org\/10.1016\/j.jtho.2016.01.020","journal-title":"J Thorac Oncol"},{"key":"3583_CR38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13000-017-0621-8","volume":"12","author":"K Ericson-Lindquist","year":"2017","unstructured":"Ericson-Lindquist K, Johansson A, Leveen P et al (2017) Targeted sequencing may facilitate differential diagnostics of pulmonary tumours: a case series. Diagn Pathol 12:31. https:\/\/doi.org\/10.1186\/s13000-017-0621-8","journal-title":"Diagn Pathol"},{"key":"3583_CR39","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.lungcan.2003.10.008","volume":"44","author":"YL Chang","year":"2004","unstructured":"Chang YL, Lee YC, Liao WY, Wu CT (2004) The utility and limitation of thyroid transcription factor-1 protein in primary and metastatic pulmonary neoplasms. Lung Cancer 44:149\u2013157. https:\/\/doi.org\/10.1016\/j.lungcan.2003.10.008","journal-title":"Lung Cancer"},{"key":"3583_CR40","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF02893461","volume":"10","author":"J Moldvay","year":"2004","unstructured":"Moldvay J, Jackel M, Bogos K et al (2004) The role of TTF-1 in differentiating primary and metastatic lung adenocarcinomas. Pathol Oncol Res 10:85\u201388. https:\/\/doi.org\/10.1007\/BF02893461","journal-title":"Pathol Oncol Res"},{"key":"3583_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00428-009-0812-0","volume":"455","author":"W Sterlacci","year":"2009","unstructured":"Sterlacci W, Fiegl M, Hilbe W, Auberger J, Mikuz G, Tzankov A (2009) Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch 455:125\u2013132. https:\/\/doi.org\/10.1007\/s00428-009-0812-0","journal-title":"Virchows Arch"},{"key":"3583_CR42","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3109\/10520295.2011.591838","volume":"87","author":"J Ye","year":"2012","unstructured":"Ye J, Hameed O, Findeis-Hosey JJ et al (2012) Diagnostic utility of PAX8, TTF-1 and napsin A for discriminating metastatic carcinoma from primary adenocarcinoma of the lung. Biotech Histochem 87:30\u201334. https:\/\/doi.org\/10.3109\/10520295.2011.591838","journal-title":"Biotech Histochem"},{"key":"3583_CR43","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1365-2559.2012.04308.x","volume":"61","author":"A Warth","year":"2012","unstructured":"Warth A, Muley T, Herpel E et al (2012) Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 61:1017\u20131025. https:\/\/doi.org\/10.1111\/j.1365-2559.2012.04308.x","journal-title":"Histopathology"},{"key":"3583_CR44","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/his.12507","volume":"65","author":"J Koh","year":"2014","unstructured":"Koh J, Go H, Kim MY, Jeon YK, Chung JH, Chung DH (2014) A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers. Histopathology 65:868\u2013878. https:\/\/doi.org\/10.1111\/his.12507","journal-title":"Histopathology"},{"key":"3583_CR45","doi-asserted-by":"publisher","first-page":"63442","DOI":"10.18632\/oncotarget.18828","volume":"8","author":"T Bian","year":"2017","unstructured":"Bian T, Zhao J, Feng J et al (2017) Combination of cadherin-17 and SATB homeobox 2 serves as potential optimal makers for the differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal adenocarcinoma. Oncotarget 8:63442\u201363452. https:\/\/doi.org\/10.18632\/oncotarget.18828","journal-title":"Oncotarget"},{"key":"3583_CR46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/cncy.21644","volume":"123","author":"TC Brandler","year":"2015","unstructured":"Brandler TC, Jelloul FZ, Soto D, Das K, Rosen L, Bhuiya TA (2015) Young investigator challenge: cadherin-17 and SATB2 in cytology specimens: do these new immunostains help in differentiating metastatic colorectal adenocarcinoma from adenocarcinomas of other origins? Cancer Cytopathol 123:706\u2013713. https:\/\/doi.org\/10.1002\/cncy.21644","journal-title":"Cancer Cytopathol"},{"key":"3583_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1002\/path.1947","volume":"209","author":"K Tsuta","year":"2006","unstructured":"Tsuta K, Ishii G, Nitadori J et al (2006) Comparison of the immunophenotypes of signet-ring cell carcinoma, solid adenocarcinoma with mucin production, and mucinous bronchioloalveolar carcinoma of the lung characterized by the presence of cytoplasmic mucin. J Pathol 209:78\u201387. https:\/\/doi.org\/10.1002\/path.1947","journal-title":"J Pathol"},{"key":"3583_CR48","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/his.12899","volume":"68","author":"S Strickland","year":"2016","unstructured":"Strickland S, Parra-Herran C (2016) Immunohistochemical characterization of appendiceal mucinous neoplasms and the value of special AT-rich sequence-binding protein 2 in their distinction from primary ovarian mucinous tumours. Histopathology 68:977\u2013987. https:\/\/doi.org\/10.1111\/his.12899","journal-title":"Histopathology"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-023-03583-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-023-03583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T02:04:28Z","timestamp":1723773868000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-023-03583-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3583"],"URL":"https:\/\/doi.org\/10.1007\/s00428-023-03583-w","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,22]]},"assertion":[{"value":"30 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analyses of the cohorts were conducted in adherence to the Declaration of Helsinki and were approved by the regional ethical review boards in Uppsala (Dnr 2012\/532) and Lund (Dnr 2004\/762 with addition 2008\/702 and Dnr 2007\/445 with additions 2008\/35 and 2014\/748, respectively).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}